Zavegepant hydrochloride
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2023
- First approval year
- 2023
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Zavegepant hydrochloride
- Molecular weight
- 675.28
- Structure (SMILES)
- Cc1cc(C[C@@H](NC(=O)N2CCC(c3cc4ccccc4[nH]c3=O)CC2)C(=O)N2CCN(C3CCN(C)CC3)CC2)cc2cn[nH]c12.Cl
- zavzpret
- Zavzpret
- bhv 3500 hydrochloride
- BHV-3500 hydrochloride
- bms 742413 03
- bms 742413 hydrochloride
- BMS-742413 hydrochloride
- BMS-742413-03
- zavegepant hydrochloride
- Zavegepant hydrochloride
- Zavegepant hydrochloride [USAN]
- Zavegepant hydrochloride [WHO-DD]
- zavegepant hydrochloride usan
- zavegepant hydrochloride who dd
- zavzpret
- Zavzpret
- ATC classification codes
- N02CD08
Sources for recorded values
- CAS registry numbers
- 1414976-20-7
- ChEMBL ID
- CHEMBL4650220
- InChIKey
- VQDUWCSSPSOSNA-RYWNGCACSA-N
- PubChem compound IDs
- 134819878
- FDA ingredient codes (UNII)
- 000QCM6HAL
- 2637955
- 2637956
- Applicant
- PFIZER
- Approval date
- 9 Mar 2023
- Application number
- NDA216386
- Patents
- 1
- Designations
- 0
- Earliest recorded loss of exclusivity
- 26 Jun 2034
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Drug name stem
- -gepant
Administration routes
- topical
Mechanisms of action
- Mechanism
- Calcitonin gene-related peptide type 1 receptor antagonist
- Action type
- Antagonist
- Target
- Calcitonin gene-related peptide type 1 receptor
- Protein identifier
- Q16602
Open Targets mechanisms
- Mechanism
- Calcitonin gene-related peptide type 1 receptor antagonist
- Action type
- Antagonist
- Target
- Calcitonin gene-related peptide type 1 receptor
Investigated indications
- Condition
- Migraine Disorders
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0005277
- Subject identifier
- D008881
- Condition identifier
- MONDO_0005277
- Condition identifier
- MONDO_0005277
- Highest recorded phase
- 4
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 3
- Polar surface area
- 120.67
- Calculated partition coefficient (ALogP)
- 3.45
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 6
- Heavy atoms
- 48
- Molecular formula
- C36H47ClN8O3
- Monoisotopic mass
- 674.3459651
- Natural product
- No
- 0069-3500
- 63539-135
Related records
Trials (17)
- A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department
- A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric Microsampling
- A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
- A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers
- A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
- A Study to Learn About the Study Medicine Called Zavegepant in Healthy Chinese Adult Participants
- A Study to Learn About Zavegepant as a Treatment for Multiple Migraine Attacks in Adult Participants
- A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults
- A Study to Learn How the Study Medicine Called Zavegepant is Taken Up Into Blood and Breast Milk of Healthy Breast-Feeding Women
- Acute Migraine Treatment in the ED With Gepants
- Acute Treatment Trial in Adult Subjects With Migraines
- Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
- Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine
- Randomized Trial in Adult Participants With Acute Migraines
- Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma
- Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen
- Zavegepant Intranasal Spray for the Acute Treatment of Episodic Cluster Headache
Approved for (1)
Targets (1)
- CALCRL Calcitonin gene-related peptide type 1 receptor antagonist